Trials / Active Not Recruiting
Active Not RecruitingNCT05081557
A Study to Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitinib in Adult and Adolescent (>=12 Years Old) Participants With Atopic Dermatitis
Real World Utilization of Upadacitinib in Adult and Adolescent Patients Living With Moderate to Severe Atopic Dermatitis (AD-VISE)
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 873 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
Atopic dermatitis (AD; also known as atopic eczema) is an inflammatory skin disease. The safety and effectiveness of upadacitinib for AD has been well-documented in previous studies, however, important information is missing on the use patterns and outcomes with upadacitinib in a real-world setting. Therefore, the purpose of this observational study is to help inform real-world usage patterns regarding the safety and effectiveness and duration of response of upadacitinib in adolescent and adult AD participants \>=12 years old in the real-world setting. Upadacitinib is an approved drug being developed for the treatment of AD. Around 975 adolescent and adult participants who are prescribed upadacitinib for the treatment of AD in routine clinical practice will be enrolled worldwide. Participants will receive oral upadacitinib as prescribed by their physician. Data from these participants will be collected for approximately 2 years. There will be no additional burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the course of the study at a hospital or clinic and will be asked to provide additional information by questionnaire at each visit.
Conditions
Timeline
- Start date
- 2021-11-17
- Primary completion
- 2026-10-01
- Completion
- 2026-10-01
- First posted
- 2021-10-18
- Last updated
- 2025-08-14
Locations
140 sites across 16 countries: Argentina, Australia, Austria, Canada, Czechia, Greece, Hungary, Israel, Italy, Mexico, Poland, Russia, Spain, Switzerland, Taiwan, United Arab Emirates
Source: ClinicalTrials.gov record NCT05081557. Inclusion in this directory is not an endorsement.